An Open-label, Multi-center, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced Soft Tissue Sarcoma

Trial Profile

An Open-label, Multi-center, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced Soft Tissue Sarcoma

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Eribulin (Primary)
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms Study 217
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 26 Mar 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 29 Feb 2016 According to an Eisai media release, based on the results of this trial, eribulin mesylate (Halaven) received approval in Japan for use in the treatment of patients with soft tissue sarcoma.
    • 15 Jul 2014 Planned End Date changed from 1 Jan 2014 to 1 Apr 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top